BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30686074)

  • 1. Genetic mutations in chronic lymphocytic leukemia: impact on clinical treatment.
    Condoluci A; Rossi D
    Expert Rev Hematol; 2019 Feb; 12(2):89-98. PubMed ID: 30686074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.
    Nabhan C; Raca G; Wang YL
    JAMA Oncol; 2015 Oct; 1(7):965-74. PubMed ID: 26181643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Features: Impact on Pathogenesis and Treatment of Chronic Lymphocytic Leukemia.
    Tausch E; Mertens D; Stilgenbauer S
    Oncol Res Treat; 2016; 39(1-2):34-40. PubMed ID: 26890126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
    Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
    Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia.
    Rossi D; Gerber B; Stüssi G
    Leuk Lymphoma; 2017 Jul; 58(7):1548-1560. PubMed ID: 27808579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib.
    Machnicki MM; Górniak P; Pępek M; Szymczyk A; Iskierka-Jażdżewska E; Steckiewicz P; Bluszcz A; Rydzanicz M; Hus M; Płoski R; Makuch-Łasica H; Nowak G; Juszczyński P; Jamroziak K; Stokłosa T; Puła B
    Eur J Haematol; 2021 Mar; 106(3):320-326. PubMed ID: 33190294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia.
    Robak P; Robak T
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1249-1265. PubMed ID: 28942659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab for chronic lymphocytic leukemia.
    Robak T
    Expert Opin Biol Ther; 2012 Apr; 12(4):503-15. PubMed ID: 22369284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of NOTCH1, MYD88, and SF3B1 mutations in Polish patients with chronic lymphocytic leukemia.
    Putowski M; Podgórniak M; Piróg M; Knap J; Zaleska J; Purkot J; Zawiślak J; Zakrzewska E; Karczmarczyk A; Własiuk P; Subocz E; Giannopoulos K
    Pol Arch Intern Med; 2017 Apr; 127(4):238-244. PubMed ID: 28424451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to Choose the Best Treatment and Testing for Chronic Lymphocytic Leukemia in the Tsunami of New Treatment Options.
    Yeung CCS; Shadman M
    Curr Oncol Rep; 2019 Jul; 21(8):74. PubMed ID: 31327069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on: molecular genetics of high-risk chronic lymphocytic leukemia.
    Moia R; Patriarca A; Deambrogi C; Rasi S; Favini C; Kodipad AA; Schipani M; Gaidano G
    Expert Rev Hematol; 2020 Feb; 13(2):109-116. PubMed ID: 31774349
    [No Abstract]   [Full Text] [Related]  

  • 12. Chronic lymphocytic leukemia (CLL)-Then and now.
    Rai KR; Jain P
    Am J Hematol; 2016 Mar; 91(3):330-40. PubMed ID: 26690614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
    Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
    Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Refractoriness in Chronic Lymphocytic Leukemia: Old and New Molecular Biomarkers.
    Maher N; Mouhssine S; Matti BF; Alwan AF; Gaidano G
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT.
    Bilous NI; Abramenko IV; Chumak AA; Dyagil IS; Martina ZV; Saenko V; Bazyka DA
    Probl Radiac Med Radiobiol; 2018 Dec; 23():283-301. PubMed ID: 30582853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.
    Jacobs RW; Awan FT; Leslie LA; Usmani SZ; Ghosh N
    Expert Rev Hematol; 2016 Dec; 9(12):1177-1187. PubMed ID: 27791448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene mutations in chronic lymphocytic leukemia.
    Amin NA; Malek SN
    Semin Oncol; 2016 Apr; 43(2):215-21. PubMed ID: 27040699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigational treatments for chronic lymphocytic leukemia: a focus on phase 1 and 2 clinical trials.
    Iskierka-Jażdżewska E; Robak T
    Expert Opin Investig Drugs; 2020 Jul; 29(7):709-722. PubMed ID: 32407139
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostication in chronic lymphocytic leukemia.
    Moia R; Gaidano G
    Semin Hematol; 2024 Apr; 61(2):83-90. PubMed ID: 38523019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chronic lymphocytic leukemia : treatment concepts in transition].
    Eichhorst B; Hallek M
    Internist (Berl); 2015 Apr; 56(4):374-80. PubMed ID: 25776793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.